What drove the pre-market move in ALSEN.PA stock today?

The pre-market gain to **EUR 0.43** was driven by elevated volume and positioning ahead of Sensorion’s earnings on **12 Mar 2026**, plus renewed interest in its OTOF-GT gene-therapy program and sector event-driven flows.

What is Meyka AI's forecast and how does it compare to current ALSEN.PA stock price?

Meyka AI's forecast model projects **EUR 0.14** over 12 months. Versus the current price **EUR 0.43**, that implies a model-based downside of **-67.44%**. Forecasts are model-based projections and not guarantees.

What are realistic price targets for ALSEN.PA stock?

Scenario targets: Bear **EUR 0.25** (-41.86%), Base **EUR 0.60** (+39.53%), Bull **EUR 1.00** (+132.56%). Targets depend on trial readouts, partnerships, and funding news.

How risky is ALSEN.PA stock for portfolio investors?

ALSEN.PA stock is high risk. Key risks are clinical failures, regulatory delays, and dilution. Liquidity spikes can amplify moves. Use small position sizes and monitor catalysts closely.

EU Stocks

ALSEN.PA Sensorion SA EURONEXT +13.87% pre-market 06 Mar 2026: catalysts ahead

ByHuzaifa Zahoor March 6, 2026March 6, 2026

ALSEN.PA stock leads pre-market gainers after a 13.87% jump to EUR 0.43 on EURONEXT on 06 Mar 2026, with 6,665,404 shares traded so far. The move follows renewed investor interest in Sensorion SA’s gene-therapy pipeline and an upcoming earnings update on 12 Mar 2026. We review valuation, technicals, Meyka AI grade, and scenario price targets so investors understand why Sensorion (ALSEN.PA) is a top pre-market gainer in the Healthcare/Biotechnology segment today.